CClinicalTrials.gg
Sign In
Not yet recruitingNCT07795151MSC-PBC-I/IIUpdated Aug 31, 2026

Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis

A Phase 1/2 interventional study of Standard background therapy and Placebo in Primary Biliary Cholangitis, sponsored by Beijing 302 Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Beijing 302 Hospital · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This phase I/II clinical trial evaluates human umbilical cord-derived mesenchymal stromal cell (hUC-MSC) injection in patients with primary biliary cholangitis (PBC). The phase I component uses a 3+3 dose-escalation design with separate single-dose and multiple-dose stages to assess safety and tolerability, establish the maximum tolerated dose and recommended phase II dose, while monitoring adverse events, vital signs, laboratory parameters, and immunogenicity, and to explore preliminary efficacy signals. The phase II component is a randomized, double-blind, placebo-controlled trial with the primary endpoint of composite response of alkaline phosphatase and bilirubin at 12 weeks to evaluate efficacy, alongside continuous safety surveillance. Systematic measurements of liver function, cholestasis, immune markers, quality of life, and pruritus scores are incorporated to investigate mechanisms and potential biomarkers, aiming to generate robust clinical evidence that supports future development and clinical translation of hUC-MSC therapy for PBC.

Read the detailed description

This is a phase I/II clinical trial. The phase I component uses a conventional "3+3" dose-escalation design with three dose levels: low (1.0×10⁸ cells), medium (1.5×10⁸ cells), and high (2.0×10⁸ cells). Each dose cohort enrolls 3-6 evaluable participants, for a total of 18-36 evaluable subjects. Phase Ia is a single-dose stage, with dose-limiting toxicity (DLT) assessed up to 7 days after the infusion. Phase Ib is a multiple-dose stage, in which participants receive one intravenous infusion weekly for 3 consecutive weeks, and DLT is evaluated up to 28 days after the first dose. The aim is to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D).

The phase II component plans to enroll 50 patients with primary biliary cholangitis, who will be randomized in a 2:2:1 ratio to receive either dose level 1 (1.5×10⁸ cells), dose level 2 (2.0×10⁸ cells), or placebo control, with the final dose to be confirmed based on the results of phase I. The treatment regimen consists of one intravenous infusion weekly for 3 consecutive weeks. The primary objective of phase II is to evaluate preliminary efficacy.

02

Conditions studied

  • Primary Biliary Cholangitis
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Voluntary participation and signed informed consent.
  • Age 18 to 75 years, both genders.

  • Diagnosis of PBC per the 2025 PBC Guideline of the National Health Commission of China, meeting at least 2 of the following 3 criteria:

    1. Biochemical evidence of cholestasis (predominantly elevated ALP and GGT) with imaging excluding extrahepatic or intrahepatic large bile duct obstruction;
    2. Positive for anti-mitochondrial antibody (AMA)/AMA-M2, or other PBC-specific autoantibodies (anti-gp210, anti-sp100);
    3. Histological evidence of non-suppurative destructive cholangitis and small bile duct destruction.
  • Inadequate response to UDCA prior to enrollment, defined as ALP ≥1.67×ULN after at least 6 months of UDCA therapy (with stable dose for ≥3 months before screening).
  • 1.67×ULN ≤ ALP \< 10×ULN and total bilirubin ≤ 3×ULN at screening.
  • If taking colchicine, stable dose for ≥3 months before screening.
  • If taking medications for pruritus (e.g., cholestyramine, rifampicin, naltrexone, sertraline), stable dose for ≥3 months before screening.
  • If taking statins or ezetimibe, stable dose for ≥2 months before screening.

Exclusion criteria

Exclusion Criteria:

  • Concurrent or previous other liver diseases, including but not limited to: chronic hepatitis B, chronic hepatitis C, primary sclerosing cholangitis (PSC), complete biliary obstruction, alcoholic liver disease, autoimmune hepatitis or overlap with other autoimmune liver diseases, non-alcoholic steatohepatitis (NASH), suspected or confirmed Gilbert's syndrome.
  • Decompensated cirrhosis (defined as presence of at least one of: esophageal/gastric variceal bleeding, hepatic encephalopathy, ascites, hepatorenal syndrome) based on clinical, laboratory, imaging, or histopathological findings.
  • Any of the following laboratory abnormalities at screening: creatinine ≥1.5×ULN or creatinine clearance \<60 mL/min; ALT and/or AST >5×ULN; albumin \<30 g/L; creatine kinase >2×ULN; platelet count \< lower limit of normal; INR ≥1.5 or prothrombin activity ≤40%.
  • Diseases that may cause non-hepatic elevation of alkaline phosphatase (e.g., Paget's disease).

  • Use of prohibited medications within specified washout periods:

    1. Within 2 months before screening: fibrates and glitazones;
    2. Within 3 months before screening: obeticholic acid, azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline, budesonide and other systemic corticosteroids by long-term parenteral or oral administration only, and hepatotoxic drugs (e.g., α-methyldopa, valproate, isoniazid, nitrofurantoin);
    3. Within 12 months before screening: antibodies or immunotherapies targeting interleukins or other cytokines/chemokines.
  • Uncontrolled cardiovascular, digestive, respiratory, urinary, neurological, psychiatric disorders (including substance/alcohol abuse), immunodeficiency, or severe autoimmune diseases, or any condition that may limit life expectancy to \<2 years, or judged by the investigator as unsuitable for participation.
  • History of malignancy within the past 2 years (except localized squamous cell carcinoma of skin or treated cervical intraepithelial neoplasia), regardless of treatment or evidence of local recurrence/metastasis.
  • Received any other investigational drug or participated in another interventional clinical trial within 3 months before screening; prior use of elafibranor or seladelpar.
  • History of drug or alcohol abuse within 1 year before screening.
  • Pregnant, planning pregnancy, or women of childbearing potential unwilling to use effective contraception (≥1 method) during the study and for 30 days after last dose; breastfeeding women.
  • Co-infection with HIV or syphilis.
  • Known allergy to any component of the study drug.
  • Psychologically unstable or incapacitated, unable to provide valid informed consent or comply with study procedures.
  • Any other condition judged by the investigator as unsuitable for enrollment, or that may interfere with the analysis of study results.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Group

    Participants receive placebo infusions via peripheral intravenous infusion once weekly for 3 consecutive weeks (at Week 0, Week 1, and Week 2), in addition to background therapy as per inclusion criteria (i.e., continued stable UDCA for patients on prior UDCA, or no UDCA for those intolerant to UDCA).

    Drug: Standard background therapy · Drug: Placebo

  • Experimental
    hUC-MSC Dose Level 1 (planned 1.5×10⁸ cells, final dose TBD)

    Participants receive human umbilical cord-derived mesenchymal stromal cells (hUC-MSC) at a planned dose of 1.5×10⁸ cells per infusion (final dose to be confirmed based on the maximum tolerated dose / recommended phase II dose determined from phase I results) via peripheral intravenous infusion once weekly for 3 consecutive weeks (at Week 0, Week 1, and Week 2), in addition to background therapy as per inclusion criteria (continued stable UDCA for prior users, or no UDCA for intolerant patients).

    Drug: Standard background therapy · Biological: hUC-MSC Dose Level 1

  • Experimental
    hUC-MSC Dose Level 2 (planned 2.0×10⁸ cells, final dose TBD)

    Participants receive hUC-MSC at a planned dose of 2.0×10⁸ cells per infusion (final dose to be confirmed based on the MTD/RP2D from phase I) via peripheral intravenous infusion once weekly for 3 consecutive weeks (at Week 0, Week 1, and Week 2), in addition to background therapy as per inclusion criteria (continued stable UDCA for prior users, or no UDCA for intolerant patients).

    Drug: Standard background therapy · Biological: hUC-MSC Dose Level 2

Interventions

  • DrugStandard background therapy

    UDCA capsule 250 mg, orally, 13-15 mg/kg/day, taken with a small amount of water. This background therapy is administered only to participants who have been on a stable dose of UDCA for at least 6 months prior to enrollment (and stable for ≥3 months before screening). Participants who are intolerant to UDCA (and have not used UDCA for ≥3 months before enrollment) do not receive UDCA during the study.

  • DrugPlacebo

    Matching placebo solution (e.g., 5% human serum albumin in 0.9% saline) administered via peripheral intravenous infusion at Week 0, Week 1, and Week 2 (once weekly for 3 infusions).

  • BiologicalhUC-MSC Dose Level 1

    Human umbilical cord-derived mesenchymal stromal cells, planned at 1.5×10⁸ cells per infusion (final dose subject to confirmation based on phase I MTD/RP2D). Administered via peripheral intravenous infusion at Week 0, Week 1, and Week 2 (once weekly for 3 infusions).

  • BiologicalhUC-MSC Dose Level 2

    Human umbilical cord-derived mesenchymal stromal cells, planned at 2.0×10⁸ cells per infusion (final dose subject to confirmation based on phase I MTD/RP2D). Administered via peripheral intravenous infusion at Week 0, Week 1, and Week 2 (once weekly for 3 infusions).

05

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT) in Phase I

    Occurrence of DLT during the DLT observation period (single-dose cohort: 7 days after infusion; multiple-dose cohort: 28 days after first infusion), graded by CTCAE v6.0.

    Time frame: Up to Day 7 (single-dose) or up to Day 28 (multiple-dose).

  2. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Phase I)

    Safety and tolerability assessed by monitoring TEAEs, SAEs, and clinically significant changes in vital signs, physical examination, laboratory parameters, and 12-lead ECG.

    Time frame: Up to Day 7 (single-dose) or up to Day 28 (multiple-dose).

  3. Maximum Tolerated Dose (MTD) of hUC-MSC in PBC Patients (Phase I)

    Determination of MTD based on DLT occurrence in the 3+3 dose-escalation phase I; MTD is the highest dose with ≤1/6 participants experiencing DLT.

    Time frame: At completion of phase I dose escalation (after DLT evaluation).

  4. Composite Biochemical Response at Week 12 (Phase II)

    Proportion of participants achieving all three: ALP \< 1.67×ULN, ALP reduction ≥15% from baseline, and total bilirubin ≤ ULN at Week 12.

    Time frame: Week 12

Secondary outcomes

  1. Proportion with ALP <1.67×ULN or ALP Reduction ≥15% or TB ≤ULN at Week 12 (Phase I)

    Exploratory efficacy endpoint for phase I - participants meeting at least one of the three criteria at Week 12.

    Time frame: Week 12

  2. Change from Baseline in Alkaline Phosphatase (ALP) (Phase I)

    Absolute and percentage changes from baseline at each specified visit.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96

  3. Change from Baseline in Total Bilirubin (TB) (Phase I)

    Absolute and percentage changes from baseline at each specified visit.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96

  4. Change from Baseline in Direct Bilirubin (DBIL) (Phase I)

    Absolute and percentage changes from baseline at each specified visit.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96

  5. Change from Baseline in Alanine Aminotransferase (ALT) (Phase I)

    Absolute and percentage changes from baseline.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  6. Change from Baseline in Aspartate Aminotransferase (AST) (Phase I)

    Absolute and percentage changes from baseline.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  7. Change from Baseline in Gamma-Glutamyl Transferase (GGT) (Phase I)

    Absolute and percentage changes from baseline.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  8. Change from Baseline in Primary Biliary Cholangitis-40 (PBC-40) Total Score (Phase I)

    Scale range: 40-200; higher scores indicate worse disease-specific quality of life.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  9. Change from Baseline in Pruritus Numerical Rating Scale (NRS) Score (Phase I)

    Scale range: 0-10; higher scores indicate worse itch severity.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  10. Change from Baseline in Itchy Quality of Life (ItchyQoL) Total Score (Phase I)

    Scale range: 22-110; higher scores indicate worse itch-related quality of life.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  11. Change from Baseline in Alkaline Phosphatase (ALP) (Phase II)

    Absolute and percentage changes from baseline at each specified visit.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  12. Change from Baseline in Total Bilirubin (TB) (Phase II)

    Absolute and percentage changes from baseline at each specified visit.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  13. Change from Baseline in Direct Bilirubin (DBIL) (Phase II)

    Absolute and percentage changes from baseline at each specified visit.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  14. Change from Baseline in Alanine Aminotransferase (ALT) (Phase II)

    Absolute and percentage changes from baseline.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  15. Change from Baseline in Aspartate Aminotransferase (AST) (Phase II)

    Absolute and percentage changes from baseline.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  16. Change from Baseline in Gamma-Glutamyl Transferase (GGT) (Phase II)

    Absolute and percentage changes from baseline.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  17. Change from Baseline in Primary Biliary Cholangitis-40 (PBC-40) Total Score (Phase II)

    Scale range: 40-200; higher scores indicate worse disease-specific quality of life.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96

  18. Change from Baseline in Pruritus Numerical Rating Scale (NRS) Score (Phase II)

    Scale range: 0-10; higher scores indicate worse itch severity.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96

  19. Change from Baseline in Itchy Quality of Life (ItchyQoL) Total Score (Phase II)

    Scale range: 22-110; higher scores indicate worse itch-related quality of life.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96

  20. Change from Baseline in Serum Total Bile Acids (TBA) (Phase II)

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  21. Change from Baseline in 7α-Hydroxy-4-cholesten-3-one (C4) (Phase II)

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  22. Change from Baseline in Fibroblast Growth Factor 19 (FGF-19) (Phase II)

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48, 72, 96.

  23. Change from Baseline in Liver Stiffness by Transient Elastography (Phase II)

    Change in liver stiffness measurement (kPa) at Week 12.

    Time frame: Baseline and Week 12.

Other outcomes

  1. Change from Baseline in Immunoglobulins (IgG, IgM) - (Phase I)

    Exploratory immune function endpoint.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48.

  2. Change from Baseline in Lymphocyte Subsets (Phase II)

    Exploratory immune markers including CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ ratio.

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48.

  3. Change from Baseline in Cytokines (Phase II)

    Exploratory cytokine marker including Interleukin-6 (IL-6), Interleukin-10 (IL-10), Tumor Necrosis Factor-α (TNF-α), and Interferon-γ (IFN-γ).

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48.

  4. Change from Baseline in C-Reactive Protein (CRP) (Phase II)

    Time frame: Baseline, Day 3, Week 1, 2, 4, 12, 24, 48.

06

Study locations

1 site
  • Beijing 302 Hospital
    Beijing, Beijing Municipality, China
07

References and documents

Publications

  • Phang MWL, Hisam NSM, Supandi F, Cheng PG, Lim SH, Lim LW, Wong KH. The Tiger Milk Medicinal Mushroom Lignosus rhinocerus (Agaricomycetes) Mitigates Oxidative Damage in a Cellular Model Mimicking Friedreich's Ataxia. Int J Med Mushrooms. 2025;27(11):63-87. doi: 10.1615/IntJMedMushrooms.2025059734. PubMed 40752029 ↗
  • Chen W, Lin F, Feng X, Yao Q, Yu Y, Gao F, Zhou J, Pan Q, Wu J, Yang J, Yu J, Cao H, Li L. MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation. Asian J Pharm Sci. 2024 Feb;19(1):100889. doi: 10.1016/j.ajps.2024.100889. Epub 2024 Feb 12. PubMed 38419761 ↗
  • Zheng X, Tian S, Li T, Zhang S, Zhou X, Liu Y, Su R, Zhang M, Li B, Qi C, Guo G, Ma S, Sun K, Yang F, Hu Y, Yang C, Cui L, Shang Y, Guo C, Jin B, Guan L, Wang J, Ning W, Han Y. Host FSTL1 defines the impact of stem cell therapy on liver fibrosis by potentiating the early recruitment of inflammatory macrophages. Signal Transduct Target Ther. 2025 Mar 7;10(1):81. doi: 10.1038/s41392-025-02162-6. PubMed 40050288 ↗
  • Ye Y, Zhang X, Su D, Ren Y, Cheng F, Yao Y, Shi G, Ji Y, Chen S, Shi P, Dai L, Su X, Deng H. Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn's colon fibrosis is improved by IFN-gamma and kynurenic acid priming through indoleamine 2,3-dioxygenase-1 signaling. Stem Cell Res Ther. 2022 Sep 8;13(1):465. doi: 10.1186/s13287-022-03157-8. PubMed 36076306 ↗
  • Wang L, Han Q, Chen H, Wang K, Shan GL, Kong F, Yang YJ, Li YZ, Zhang X, Dong F, Wang Q, Xu D, Hu ZJ, Wang SH, Keating A, Bi YL, Zhang FC, Zhao RC. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev. 2014 Oct 15;23(20):2482-9. doi: 10.1089/scd.2013.0500. Epub 2014 Jul 16. PubMed 24835895 ↗
  • Shokati A, Nikbakht M, Sahraian MA, Saeedi R, Asadollahzadeh E, Rezaeimanesh N, Chahardouli B, Gharaylou Z, Mousavi SA, Ai J, Naser Moghadasi A. Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial. Sci Rep. 2025 May 8;15(1):16005. doi: 10.1038/s41598-025-00590-6. PubMed 40341605 ↗
  • Shi L, Zhang Z, Mei S, Wang Z, Xu Z, Yao W, Liu L, Yuan M, Pan Y, Zhu K, Liu K, Meng F, Sun J, Liu W, Xie X, Dong T, Huang L, Meng F, Fu JL, Li Y, Zhang C, Fan X, Shi M, Zhang Y, Li Y, Xie WF, Zhang P, Wang FS. Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights. Signal Transduct Target Ther. 2025 Jul 29;10(1):238. doi: 10.1038/s41392-025-02318-4. PubMed 40721581 ↗
  • Li L, He Y, Zhao J, Yin H, Feng X, Fan X, Wu W, Lu Q. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases. Clin Rev Allergy Immunol. 2025 Feb 21;68(1):21. doi: 10.1007/s12016-025-09030-9. PubMed 39982546 ↗
  • Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022 Aug 6;7(1):272. doi: 10.1038/s41392-022-01134-4. PubMed 35933430 ↗
  • Gholamrezanezhad A, Mirpour S, Bagheri M, Mohamadnejad M, Alimoghaddam K, Abdolahzadeh L, Saghari M, Malekzadeh R. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol. 2011 Oct;38(7):961-7. doi: 10.1016/j.nucmedbio.2011.03.008. Epub 2011 Jun 22. PubMed 21810549 ↗
  • Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014 Nov;15(11):1009-16. doi: 10.1038/ni.3002. PubMed 25329189 ↗
  • Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014 Mar;32(3):252-60. doi: 10.1038/nbt.2816. Epub 2014 Feb 23. PubMed 24561556 ↗
  • Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7. doi: 10.1126/science.284.5411.143. PubMed 10102814 ↗
  • Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004. PubMed 29859173 ↗
  • You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022 Feb;16(1):1-23. doi: 10.1007/s12072-021-10276-6. Epub 2022 Feb 4. No abstract available. PubMed 35119627 ↗
  • Levy C, Manns M, Hirschfield G. New Treatment Paradigms in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2076-2087. doi: 10.1016/j.cgh.2023.02.005. Epub 2023 Feb 19. PubMed 36809835 ↗
  • Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. J Clin Transl Hepatol. 2020 Mar 28;8(1):49-60. doi: 10.14218/JCTH.2019.00049. Epub 2020 Jan 29. PubMed 32274345 ↗
  • Rodrigues PM, Perugorria MJ, Santos-Laso A, Bujanda L, Beuers U, Banales JM. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure? J Hepatol. 2018 Dec;69(6):1371-1383. doi: 10.1016/j.jhep.2018.08.020. Epub 2018 Sep 5. PubMed 30193962 ↗

Individual participant data

Plan to share: Yes — After approval from the steering committee and the Human Genetic ResourcesAdministration of China, this trial data can be shared with qualifying researchers whosubmit a proposal with a valuable research question. A contract should be signed.

08

Registry details

Key details

Study ID
NCT07795151
Lead sponsor
Beijing 302 Hospital
Responsible party
Fu-Sheng Wang (Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 302 Hospital) — Principal investigator
First posted
Aug 31, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

Lei Shi, MD, PhD
Contact
shilei302@126.com
86-10-66949623
Fu-Sheng Wang, MD, PhD
Contact
fswang302@163.com
86-10-66933332
Fu-Sheng Wang, MD, PhD
study chair · The Fifth Medical Center of PLAGeneral Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Cirrhosis, Biliary→

Other studies from this sponsor

Beijing 302 Hospital

Start the discussion